HemoGenyx Pharmaceuticals PLC (LONHEMO) said that its chief operating officer is leaving as it unveiled a new senior appointment.
Lawrence Pemble is exiting immediately. Andrew Wright, meanwhile, is coming in as financial controller and company secretary, a “non-board position”.
Wright is a trained accountant who is currently the director of corporate development for Thomas Murray, a post-trade capital markets data and advisory firm and is an executive director of Trayned Insight, a data science company serving the healthcare and pharmaceutical industries.
Hemogenyx chief executive, Dr Vladislav Sandler, said: "I am delighted to welcome Andrew to the team and look forward to his support as we continue to advance the development of our novel therapeutic products for patients with blood and severe autoimmune diseases.
“I would also like to extend my thanks to Lawrence for his contribution to the board and we wish him well in his next ventures."
The company is developing technology that could transform bone marrow transplantation and the treatment of blood diseases.